SEC Filing - MiNK Therapeutics

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

WIINBERG ULF

(Last)

(First)

(Middle)

149 FIFTH AVENUE, SUITE 500

(Street)

NEW YORK

10010

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/13/2021

3. Issuer Name and Ticker or Trading Symbol
MiNK Therapeutics, Inc. [ INKT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	278,300	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽¹⁾	11/19/2028	Common Stock	27,830	0.02	D
Stock Option (Right to Buy)	⁽²⁾	01/30/2030	Common Stock	111,320	0.01	D
Stock Option (Right to Buy)	⁽³⁾	02/11/2031	Common Stock	20,872	3.03	D

Explanation of Responses:

1. Represents an option to purchase shares of the common stock, which vests in three equal annual installments beginning on November 19, 2019.

2. Represents an option to purchase shares of our common stock, which vested as to 33% of the underlying shares on January 30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.

3. Represents an option to purchase shares of the common stock, which vests fully on February 11, 2022.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Christine Klaskin, attorney-in-fact	10/20/2021
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

                             LIMITED POWER OF ATTORNEY

    The undersigned hereby constitutes and appoints Jennifer S. Buell and
Christine M. Klaskin, and each of them individually, with full power of
substitution, as the undersigned's true and lawful attorney-in-fact to:

    (1)   prepare, execute in the undersigned's name and on the undersigned's
          behalf, and submit to the U.S. Securities and Exchange Commission (the
          "SEC") a Form ID, including amendments thereto, and any other
          documents necessary or appropriate to obtain codes and passwords
          enabling the undersigned to make electronic filings with the SEC of
          reports required by Section 16(a) of the Securities Exchange Act of
          1934, as amended, or any rule or regulation of the SEC;

    (2)   execute for and on behalf of the undersigned, in the undersigned's
          capacity as officer and/or director of MiNK Therapeutics, Inc. (the
          "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in accordance
          with Section 16(a) of the Securities Exchange Act of 1934, as amended,
          and the rules thereunder;

    (3)   do and perform any and all acts for and on behalf of the undersigned
          that may be necessary or desirable to complete and execute any such
          Form 3, 4, or 5 or Schedule 13D or 13G, complete and execute any
          amendment or amendments thereto, and timely file such form with the
          SEC and any stock exchange or similar authority; and

    (4)   take any other action of any type whatsoever in connection with the
          foregoing that, in the opinion of each such attorney-in-fact, may be
          of benefit to, in the best interest of, or legally required by, the
          undersigned, it being understood that the documents executed by each
          such attorney-in-fact on behalf of the undersigned pursuant to this
          Power of Attorney shall be in such form and shall contain such terms
          and conditions as each such attorney-in-fact may approve in each such
          attorney-in-fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or each
such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to
be done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that each foregoing attorney-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                    [Remainder of page intentionally left blank]


    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 20th day of October, 2021.


                                          /s/ Ulf Wiinberg
                                        -----------------------------
                                        Name: Ulf Wiinberg


                    [Signature Page to Limited Power of Attorney